Inferior mesenteric vein thrombosis in an elderly woman with antiphospholipid syndrome: A case report and review of the literature Authors: Ian Seng Lam, Hoi Ip Leong, Tam Fei Chang Published: 2026 ABSTRACT AbstractInferior mesenteric vein (IMV) thrombosis is a rare but potentially fatal subset of mesenteric venous thrombosis (MVT). We report a 75-year-old woman presenting with epigastric pain, fever, and Escherichia coli bacteremia, found to have isolated Inferior mesenteric vein thrombosis on contrast-enhanced computed tomography. Conservative management with bowel rest, anticoagulation, and antibiotics led to clinical improvement and partial thrombus regression. Subsequent workup revealed antiphospholipid syndrome with associated protein C, S, and antithrombin III deficiencies. This case underscores that early diagnosis and prompt intervention significantly improve prognosis, and highlights the need for heightened clinical awareness of Inferior mesenteric vein thrombosis given its nonspecific presentation and life-threatening potential.Keywords: Inferior mesenteric vein, Thrombosis, Sepsis, Antiphospholipid syndrome, Case report Introduction Mesenteric venous thrombosis (MVT) is a rare and potentially life-threatening condition. It results from thrombotic obstruction of the superior mesenteric vein (SMV), inferior mesenteric vein (IMV), splenic vein (SV), or portal vein (PV), which can lead to intestinal infarction, sepsis and bowel perforation. MVT is commonly defined as thrombosis involving the SMV, with or without extension into the PV or splenic vein SV; although the thrombotic process may originate in the small venous arcades or a major trunk and can affect the PV, the SMV is implicated in over 90% of cases, whereas the IMV is involved in up to 11%, with concurrent involvement of multiple venous segments—most frequently the PV and SMV, followed by the SV and IMV—being a common finding [[1], [2], [3]]. MVT accounts for approximately 5%-15% of all cases of acute mesenteric ischemia and represents about 1 in 1000 emergency department admissions. The estimated incidence of MVT is approximately 2.7 per 100,000 person-years. The median age of presentation is between 45 and 60 years, with a male-to-female ratio showing a slight male predominance [[1], [2], [3], [4], [5]]. Risk factors and etiologies for MVT are multifaceted. Hypercoagulable states, either inherited or acquired, are identifiable in 60% to 75% of patients. Inherited thrombophilias include Factor V Leiden mutation, deficiencies in antithrombin III or proteins C and S, and excess prothrombotic factors. Acquired hypercoagulable conditions encompass myeloproliferative neoplasms (eg, polycythemia vera, essential thrombocythemia), antiphospholipid syndrome, malignancy, oral contraceptive use, and pregnancy. Local inflammatory or traumatic abdominal processes, such as pancreatitis, diverticulitis, inflammatory bowel disease, and recent surgery, frequently serve as precipitating events, often in conjunction with an underlying thrombophilia. Stasis from portal hypertension (eg, in cirrhosis or heart failure) is another contributing factor. While up to 20%-30% of cases may initially be deemed idiopathic, a thorough workup, including testing for the JAK2V617F mutation, can unveil an underlying myeloproliferative neoplasm or other constitutional predisposition [[1], [2], [3], [4], [5], [6], [7], [8]]. Case presentation A 75-year-old woman presented to the emergency department with a 2-day history of epigastric pain and a 1-day history of fever and chills. She reported no cough, dyspnea, vomiting, or dysuria. Her past medical history was significant for type 2 diabetes mellitus and hypertension. On admission, her vital signs were as follows: temperature 39.7°C, blood pressure 136/93 mmHg, heart rate 115 beats per minute, and oxygen saturation 98% on room air. Physical examination revealed epigastric tenderness without guarding or rebound. Murphy's sign was negative, McBurney's point was non-tender, and bowel sounds were normal. Initial investigations included a chest X-ray, which showed no evidence of pneumonia or pneumoperitoneum. Laboratory findings revealed an elevated white blood cell (WBC) count (14.3 × 10⁹/L), increased C-reactive protein (CRP) (21.4 mg/dL), and markedly elevated procalcitonin (PCT) (58 ng/mL). A subsequent contrast-enhanced computed tomography (CT) scan of the abdomen and pelvis revealed thrombotic occlusion of the IMV, characterized by intraluminal filling defects and surrounding fat stranding, along with mild thickening of the large bowel loops (Figs. 1, 2). Contrast-enhanced CT of the abdomen and pelvis performed during the venous phase revealed an intraluminal filling defect involving the inferior mesenteric vein (white arrow). Contrast-enhanced CT of the abdomen and pelvis performed during the venous phase revealed extensive thrombosis involving the inferior mesenteric vein and its tributaries, accompanied by surrounding mesenteric edema (white arrow). The patient was admitted to the emergency ward under the impression of sepsis secondary to IMV thrombosis. Management included bowel rest (fasting), empirical broad-spectrum antibiotic therapy with meropenem, intravenous fluid resuscitation, and anticoagulation with enoxaparin. Escherichia coli was isolated from blood cultures. The isolate was subsequently tested and found to be susceptible to the empirical antibiotics administered. The patient’s clinical condition gradually improved, with resolution of fever and hemodynamic stable. No signs of bowel perforation or gastrointestinal bleeding were observed during the admission. A comprehensive etiological workup was pursued to elucidate the underlying cause of the thrombotic event. Laboratory tests revealed positive anticardiolipin antibodies and decreased activity levels of protein C, protein S, and antithrombin III. A hematology consultation was obtained, and a diagnosis of antiphospholipid syndrome (APS)-induced IMV thrombosis was established. Long-term anticoagulation with warfarin was recommended. A follow-up abdomen and pelvic CT scan performed on hospital day 7 demonstrated partial regression of the IMV thrombus (Fig. 3). The patient remained clinically stable, with resolution of abdominal pain, tolerance to oral intake, and normal bowel function. The patient was discharged in stable condition on hospital day 12. Contrast-enhanced CT of the abdomen and pelvis in the venous phase. (A) Initial scan reveals a filling defect in the inferior mesenteric vein and its tributaries (white arrow), indicating thrombosis. (B) Follow-up CT scan after one week of treatment shows a partially recanalized filling defect in the inferior mesenteric vein (white arrow). Discussion MVT may present as either an acute or chronic process. Acute mesenteric venous thrombosis (AMVT) and chronic mesenteric venous thrombosis (CMVT) are considered successive stages of the same disease entity and share similar underlying etiologies; however, their clinical management differs substantially. The distinction is primarily based on the temporal course of symptoms relative to presentation. Patients with symptom onset within four weeks are arbitrarily defined as having AMVT. In contrast, CMVT refers to patients with symptoms persisting for more than four weeks in the absence of bowel infarction, or those in whom MVT is discovered incidentally on abdominal imaging [2,3]. AMVT is the least common cause of acute mesenteric infarction, accounting for 5% to 15% of all cases. Thrombosis most frequently involves the SMV, whereas the IMV is implicated in up to 10% of cases [1]. The mean age at presentation ranges from 40 to 60 years, with a male predominance. The mortality of MVT remains high, largely attributable to nonspecific symptoms and delayed diagnosis [9]. Abdominal pain is the predominant symptom and is typically severe, localized to the mid-abdomen, and disproportionate to physical examination findings. Associated symptoms may include nausea, vomiting, diarrhea, or gastrointestinal bleeding. Additional reported features include constipation, anorexia, fever, and chills. The presence of fever and chills at disease onset may indicate bacteremia, pylephlebitis, or infected portal venous thrombosis, often secondary to intra-abdominal infections such as acute diverticulitis or appendicitis [[1], [2], [3]]. Approximately 75% of patients experience symptoms for more than 48 hours before seeking medical attention, with the mean duration of symptoms ranging from 6 to 14 days. As intestinal ischemia progresses, abdominal signs such as tenderness, distention, and ascites may develop. Patients may present with dehydration due to volume loss or third-space fluid sequestration. In severe cases, peritoneal signs—including rebound tenderness, guarding, or rigidity—may emerge as a result of transmural infarction and bowel gangrene. Hemodynamic instability is observed in approximately 6% to 29% of patients, particularly in those with advanced disease. The presence of peritoneal signs, hemodynamic compromise, and fever suggests severe disease with bowel infarction and is associated with a poor prognosis. Bowel infarction reflects transmural ischemia, which can develop rapidly; acute disruption of the intestinal mucosal barrier promotes bacterial translocation, potentially culminating in sepsis, septic shock, multisystem organ failure, and death [[1], [2], [3]]. Abdominopelvic CT with contrast enhancement is the preferred imaging modality for the diagnosis of AMVT, demonstrating a diagnostic accuracy of approximately 90%. The direct diagnostic finding is the presence of an intraluminal filling defect, visualized as a focal area of low attenuation within the affected vein. Additional venous signs include vessel expansion and the presence of a sharply defined venous wall. Associated findings suggestive of intestinal ischemia may include bowel wall thickening exceeding 3 mm, mesenteric stranding or thickening, indistinct bowel margins, and the presence of ascites. Furthermore, homogeneous bowel wall enhancement combined with wall thickening of 10 mm or more has been reported to have approximately 90% accuracy in predicting transmural intestinal infarction [[1], [2], [3], [4],9,10]. The management of MVT has evolved significantly, reducing mortality to approximately 10% [2,9], with treatment goals focused on preventing thrombus propagation and intestinal infarction acutely while managing long-term recurrence and complications. For hemodynamically stable patients without peritonitis, medical management remains the cornerstone and includes bowel rest, nasogastric decompression, fluid resuscitation, electrolyte replacement, parenteral nutrition if needed [[1], [2], [3], [4],7,10], and broad-spectrum antibiotics for fever or sepsis [1,3,4,9], prompt anticoagulation with unfractionated or low-molecular-weight heparin achieves recanalization rates of 40% to 80%, followed by transition to warfarin or direct oral anticoagulants (DOACs) for a minimum of three to six months—or indefinitely for unprovoked MVT or persistent risk factors [[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11]]. For patients with persistent symptoms, worsening abdominal pain despite anticoagulation, or signs of peritonitis, endovascular intervention should be considered [2]. In this context, interventional radiology offers catheter-directed thrombolysis via transhepatic or transjugular routes. Notably, thrombolysis via a direct venous approach has been increasingly adopted due to its potential for greater efficacy and is now performed in a growing number of centers. A recent meta-analysis by Gao et al. [12] reported that among patients receiving thrombolysis for portal venous system thrombosis, the pooled rates of overall response and complete recanalization were 93% and 58%, respectively, with a bleeding event rate of 18% and a 30-day mortality of 4%. The analysis further emphasized that early thrombolysis (≤ 14 days from symptom onset) significantly improves recanalization rates. Alternatively, transjugular intrahepatic portosystemic shunt (TIPS) placement for extensive portal vein thrombosis refractory to anticoagulation achieves recanalization rates exceeding 80% [[1], [2], [3], [4]]. Surgical intervention is reserved for patients with peritonitis, bowel perforation, or clinical deterioration, with the aim of resecting non-viable bowel while preserving intestinal length through segmental resection. However, this approach is associated with significantly higher mortality [[1], [2], [3], [4], [5],7,9]. This case describes a rare isolated inferior mesenteric vein thrombosis in an elderly woman with antiphospholipid syndrome. Isolated IMV involvement is rare, accounting for up to 11% of mesenteric venous thromboses. The patient initially presented with epigastric pain, followed by fever and chills, suggesting that abdominal symptoms preceded systemic infection. Contrast-enhanced CT revealed extensive IMV thrombosis with no evidence of alternative infectious sources such as diverticulitis or intra-abdominal abscess. The subsequent isolation of Escherichia coli from blood cultures, in the absence of another identifiable focus, supports bacterial translocation across compromised intestinal mucosa secondary to venous thrombosis. Thus, in this case, IMV thrombosis likely preceded and contributed to sepsis, rather than arising as a complication of infection. However, it should be acknowledged that IMV thrombosis can occasionally occur secondary to an underlying infectious process. Conservative management with bowel rest, anticoagulation, and antibiotics led to partial thrombus regression and clinical recovery. This favorable outcome underscores the critical role of timely diagnosis and intervention: mesenteric venous thrombosis carries a mortality of approximately 19%-23%, but prompt recognition and treatment can reduce this to below 10%. Subsequent hypercoagulable workup revealed APS with associated protein C, S, and antithrombin III deficiencies. The patient had no prior history of thromboembolic events; therefore, this episode represents the first manifestation of APS, presenting as isolated IMV thrombosis. This underscores the need for comprehensive etiologic investigation in unprovoked thrombosis, even in elderly patients. APS diagnosis mandates long-term anticoagulation to prevent recurrence. Conclusion Isolated IMV thrombosis is rare and may present with nonspecific symptoms, often delaying diagnosis. This case underscores the importance of prompt imaging and multidisciplinary management, including anticoagulation and treatment of underlying thrombophilia. Even in elderly patients, a thorough etiological workup is essential to identify conditions such as antiphospholipid syndrome, guiding long-term anticoagulation to prevent recurrence. Ethical approval The protocol was reviewed and approved by the Human Research Ethics Committee of the Conde S. Januario General Hospital at Macau. The study was performed in accordance with the Declaration of Helsinki. Patient consent A written informed consent was obtained from the patient for the publication of this case report. Footnotes Acknowledgments: The authors would like to thank the patient and her family for the permission to publish this report. Competing Interests: The authors have declared that no competing interests exist. References